CAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2025 and provided a business update.
Read more at prnewswire.com
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
Provided By PR Newswire – Last update: